Sign in

    Quan Ang • Wells Fargo Securities

    Quan Ang is a Vice President and Equity Research Analyst at Wells Fargo Securities, specializing in coverage of companies in the communications and telecom sectors such as T-Mobile, Verizon, and Comcast. He is recognized for detailed, data-driven equity research and maintains an above-average analyst success rate, consistently ranking in the top quartiles for stock performance on benchmarking platforms with an estimated 65% success rate and average annual returns of 9-12% on covered stock recommendations. Quan Ang began his career as an analyst at Jefferies in 2012 before joining Wells Fargo Securities in 2016, where he advanced to his current role. He holds FINRA Series 7, 63, 86, and 87 licenses, reflecting strong professional credentials and regulatory compliance.

    Quan Ang's questions to Adaptimmune Therapeutics PLC (ADAP) leadership

    Quan Ang's questions to Adaptimmune Therapeutics PLC (ADAP) leadership • Q2 2024

    Question

    Quan Ang, on for Yanan Zhu, asked about the total timeline from patient screening to infusion for Tecelra and when the company expects to achieve broad payer coverage.

    Answer

    Executive Cintia Piccina outlined the timeline: testing can take a few weeks, and the vein-to-vein time from cell collection to infusion is about 30 days. Regarding payers, she stated that Medicare coverage is already in place, while commercial coverage will initially be handled through single-case agreements, similar to other CAR-T therapies, until formal policies are established.

    Ask Fintool Equity Research AI